Drug-induced senescent Multiple Myeloma cells elicit NK ...€¦ · 24/04/2018 · 1 Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
1. Caligiuri MA. Human natural killer cells. Blood 2008;112(3):461-9 doi 10.1182/blood-2007-09-077438.
2. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180(4):1395-403.
3. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1(1):41-9 doi 10.1038/35095564.
4. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27(45):5932-43 doi 10.1038/onc.2008.267.
5. Gismondi A, Stabile H, Nisti P, Santoni A. Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. Front Immunol 2015;6:567 doi 10.3389/fimmu.2015.00567.
6. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91 doi 10.1111/j.1600-065X.2006.00457.x.
7. Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, et al. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget 2017 doi 10.18632/oncotarget.18185.
8. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996;87(7):2632-40.
9. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100(10):3633-8 doi 10.1182/blood-2001-12-0293.
10. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264(5161):965-8.
11. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001;97(1):14-32.
12. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 1994;13(12):2822-30.
13. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol 2002;22(2):51-6.
14. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010;127(2):85-92 doi 10.1016/j.imlet.2009.09.009.
15. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004;200(7):825-34 doi 10.1084/jem.20041389.
16. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009;206(1):25-34 doi 10.1084/jem.20082013.
17. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005;105(2):721-7 doi 10.1182/blood-2003-12-4187.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
18. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009;113(15):3503-11 doi 10.1182/blood-2008-08-173914.
19. Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J Immunol 2014;193(2):950-60 doi 10.4049/jimmunol.1400271.
20. Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology 2013;2(12):e26663 doi 10.4161/onci.26663.
21. Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, et al. Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells. Oncoimmunology 2016;5(10):e1218105 doi 10.1080/2162402X.2016.1218105.
22. Urbanelli L, Buratta S, Sagini K, Tancini B, Emiliani C. Extracellular Vesicles as New Players in Cellular Senescence. Int J Mol Sci 2016;17(9) doi 10.3390/ijms17091408.
23. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000;95(2):610-8.
24. Franciosa G, Diluvio G, Gaudio FD, Giuli MV, Palermo R, Grazioli P, et al. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. Oncogene 2016;35(36):4741-51 doi 10.1038/onc.2016.5.
25. Ulbrich L, Favaloro FL, Trobiani L, Marchetti V, Patel V, Pascucci T, et al. Autism-associated R451C mutation in neuroligin3 leads to activation of the unfolded protein response in a PC12 Tet-On inducible system. Biochem J 2016;473(4):423-34 doi 10.1042/BJ20150274.
26. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007;110(2):606-15 doi 10.1182/blood-2006-10-052720.
27. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current protocols in cell biology / editorial board, Juan S Bonifacino [et al] 2006;Chapter 3:Unit 3 22 doi 10.1002/0471143030.cb0322s30.
28. Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, et al. Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncoimmunology 2017;6(3):e1279372 doi 10.1080/2162402X.2017.1279372.
29. Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, et al. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. J Immunol 2015;195(2):736-48 doi 10.4049/jimmunol.1402643.
30. Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009;4(3):e4942 doi 10.1371/journal.pone.0004942.
31. Watson DC, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G, et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 2016;105:195-205 doi 10.1016/j.biomaterials.2016.07.003.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
32. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP, et al. Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med 2003;197(8):977-84 doi 10.1084/jem.20021836.
33. Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118 doi 10.1146/annurev-pathol-121808-102144.
34. Watanabe S, Kawamoto S, Ohtani N, Hara E. Impact of senescence-associated secretory phenotype and its potential as a therapeutic target for senescence-associated diseases. Cancer Sci 2017;108(4):563-9 doi 10.1111/cas.13184.
35. Dubois S, Conlon KC, Muller JR, Hsu-Albert J, Beltran N, Bryant BR, et al. IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK cell cytokine release capabilities. Cancer Immunol Res 2017 doi 10.1158/2326-6066.CIR-17-0279.
36. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006;177(9):6072-80.
37. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008;68(8):2972-83 doi 10.1158/0008-5472.CAN-08-0045.
38. Muller D. Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15. Oncoimmunology 2012;1(7):1213-4 doi 10.4161/onci.20824.
39. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, et al. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007;37(2):171-5 doi 10.1016/j.cyto.2007.02.022.
40. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013;210(10):2057-69 doi 10.1084/jem.20130783.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604
Published OnlineFirst April 24, 2018.Cancer Immunol Res Cristiana Borrelli, Biancamaria Ricci, Elisabetta Vulpis, et al. trans-presentationproliferation by direct or exosome-mediated IL-15 Drug-induced senescent Multiple Myeloma cells elicit NK cell
Updated version
10.1158/2326-6066.CIR-17-0604doi:
Access the most recent version of this article at:
Material
Supplementary
C1
http://cancerimmunolres.aacrjournals.org/content/suppl/2018/04/24/2326-6066.CIR-17-0604.DAccess the most recent supplemental material at:
Manuscript
Authorbeen edited. Author manuscripts have been peer reviewed and accepted for publication but have not yet
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerimmunolres.aacrjournals.org/content/early/2018/04/24/2326-6066.CIR-17-0604To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 24, 2018; DOI: 10.1158/2326-6066.CIR-17-0604